Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Anthracycline dose intensification in acute myeloid leukemia.
Inherited antithrombin deficiency: a review
Summary. Antithrombin (AT) is a potent inactivator of thrombin and factor Xa and the major inhibitor of blood coagulation. Inherited AT deficiencies are uncommon, with prevalences in the general… Expand
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors.
Clinical phenotype in systemic mastocytosis (SM) is markedly variable, which complicates prognostication and decision making regarding the choice and timing of therapy. In a retrospective study of… Expand
Eosinophilia: secondary, clonal and idiopathic
Blood eosinophilia signifies either a cytokine‐mediated reactive phenomenon (secondary) or an integral phenotype of an underlying haematological neoplasm (primary). Secondary eosinophilia is usually… Expand
A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.
- A. Tefferi, T. Lasho, +10 authors A. Pardanani
- The New England journal of medicine
- 2 September 2015
BACKGROUND Current drugs for myeloproliferative neoplasm-associated myelofibrosis, including Janus kinase (JAK) inhibitors, do not induce complete or partial remissions. Imetelstat is a 13-mer… Expand
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.
Chimeric antigen receptor T (CAR-T) cell therapy is a new pillar in cancer therapeutics; however, its application is limited by the associated toxicities. These include cytokine release syndrome… Expand
Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology.
- J. Radich, M. Deininger, +27 authors Hema M Sundar
- Journal of the National Comprehensive Cancer…
- 1 September 2018
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a… Expand
Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance
- M. Patnaik, T. Lasho, +6 authors A. Tefferi
- Biology, Medicine
- American journal of hematology
- 1 March 2013
SRSF2, SF3B1, and U2AF35 (U2AF1) are the three most frequent genes involved with spliceosome mutations in myeloid malignancies. SF3B1 mutations are most frequent (~80%) in myelodysplastic syndromes… Expand
SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival.
Among spliceosome component mutations, those involving SF3B1 are most frequent in myelodysplastic syndromes with ring sideroblasts (MDS-RS; ∼ 75% incidence) and SRSF2 in chronic myelomonocytic… Expand
Myelodysplastic syndromes: Contemporary review and how we treat
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal stem cell disorders with an inherent tendency for leukemic transformation. Diagnosis is currently based on the presence of… Expand